TY - JOUR
KW - Anxiety
KW - Anxiety Disorders/therapy
KW - Asthma/epidemiology
KW - chronic medical conditions
KW - collaborative care
KW - Depression
KW - Female
KW - Gastrointestinal Diseases/epidemiology
KW - Humans
KW - Interventions
KW - Male
KW - Migraine Disorders/epidemiology
KW - Primary Health Care
AU - B. L. Rollman
AU - J. C. Huffman
A1 - 
AB - Patients with chronic medical conditions (CMCs) and a comorbid anxiety or mood disorder tend to report more symptoms and experience poorer treatment outcomes compared with those without mental health comorbidity. Although the benefits to be derived from treating depression in patients with CMCs have begun to be quantified, particularly among those with cardiovascular disease, our understanding of the benefits of treating anxiety in patients with CMCs is far less developed. Improving care for patients with CMCs is one of the major challenges facing medicine today because patients with multiple chronic diseases account for most health care costs. Emerging evidence indicates that integrated or "blended" collaborative care strategies that treat both the psychiatric and physical conditions together tend to produce greater improvements in mood symptoms and control of CMCs compared with programs that target the psychiatric condition alone. We review a new report, published in this issue of Psychosomatic Medicine, from the National Institutes of Mental Health-funded multisite Coordinated Anxiety Learning and Management trial, that shines new attention on anxiety disorders and medical comorbidity. We place their findings in context with these new blended care models that are potentially more powerful, scalable, cost-effective, and readily delivered through existing CMC programs.
BT - Psychosomatic medicine
C5 - General Literature
CP - 8
CY - United States
DO - 10.1097/PSY.0000000000000011
IS - 8
JF - Psychosomatic medicine
N2 - Patients with chronic medical conditions (CMCs) and a comorbid anxiety or mood disorder tend to report more symptoms and experience poorer treatment outcomes compared with those without mental health comorbidity. Although the benefits to be derived from treating depression in patients with CMCs have begun to be quantified, particularly among those with cardiovascular disease, our understanding of the benefits of treating anxiety in patients with CMCs is far less developed. Improving care for patients with CMCs is one of the major challenges facing medicine today because patients with multiple chronic diseases account for most health care costs. Emerging evidence indicates that integrated or "blended" collaborative care strategies that treat both the psychiatric and physical conditions together tend to produce greater improvements in mood symptoms and control of CMCs compared with programs that target the psychiatric condition alone. We review a new report, published in this issue of Psychosomatic Medicine, from the National Institutes of Mental Health-funded multisite Coordinated Anxiety Learning and Management trial, that shines new attention on anxiety disorders and medical comorbidity. We place their findings in context with these new blended care models that are potentially more powerful, scalable, cost-effective, and readily delivered through existing CMC programs.
PP - United States
PY - 2013
SN - 1534-7796; 0033-3174
SP - 710
EP - 712
EP - 
T1 - Treating anxiety in the presence of medical comorbidity: calmly moving forward
T2 - Psychosomatic medicine
TI - Treating anxiety in the presence of medical comorbidity: calmly moving forward
U1 - General Literature
U2 - 24096773
U3 - 10.1097/PSY.0000000000000011
VL - 75
VO - 1534-7796; 0033-3174
Y1 - 2013
ER -